RedHill Biopharma Ltd. (NASDAQ:RDHL) finished Wednesday with a subtraction of -$0.01 to close at $0.61, a downside of -2.18 percent. An average of 1,082,960 shares of common stock have been traded in the last five days. There was a fall of -$0.2249 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 786,390 shares traded, while the 50-day average volume stands at 1,130,256.
RDHL stock has decreased by -34.52% in the last month. The company shares reached their 1-month lowest point of $0.6020 on 09/21/22. With the stock rallying to its 52-week high on 03/23/22, shares of the company touched a low of $0.61 and a high of $6.50 in 52 weeks. It has reached a new high 4 times so far this year and lost -76.36% or -$1.9701 in price. In spite of this, the price is down -90.62% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
RedHill Biopharma Ltd. (RDHL) stock’s beta is 1.80. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.42.
The quick ratio of RedHill Biopharma Ltd. for the three months ended March 30 was 0.80, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Its gross profit as reported stood at $36.35 million compared to revenue of $85.76 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, RedHill Biopharma Ltd.’s return on assets was -49.90%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $97.74 million in the quarter, while revenues were grew 22.07%. The analyst consensus anticipated RedHill Biopharma Ltd.’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.3, a -30.40% surprise. For the quarter, EBITDA amounted to -$12.7 million.
From a technical analysis perspective, let’s take a brief look at RedHill Biopharma Ltd. (RDHL) price momentum. RSI 9-day as of the close on 21 September was 15.08%, suggesting the stock is oversold, with historical volatility in this time frame at 51.38%.
As of today, RDHL’s price is $0.6867 -26.94% or -$0.2249 from its 5-day moving average. RDHL is currently trading -33.25% lower than its 20-day SMA and -66.12% lower than its 100-day SMA. However, the stock’s current price level is -40.21% below the SMA50 and -76.08% below the SMA200.
The stochastic %K and %D were 5.84% and 6.97%, respectively, and the average true range (ATR) was 0.0605. With the 14-day stochastic at 2.65% and the average true range at 0.0632, the RSI (14) stands at 24.77%. The stock has reached -0.1268 on the 9-day MACD Oscillator while the 14-day reading was at -0.1623.
Cantor Fitzgerald launched coverage on RedHill Biopharma Ltd. (NASDAQ: RDHL) in its analyst report released on August 31, 2021. The firm assigned the stock an Overweight rating. The consensus rating for RedHill Biopharma Ltd. (RDHL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RDHL, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is RDHL’s price target for the next 12 months?
Analysts predict a range of price targets between $4.50 and $11.00, with a median target of $11.00. Taking a look at these predictions, the average price target given by analysts for RedHill Biopharma Ltd. (RDHL) stock is $8.83.